Consenso nacional sobre el diagnóstico, estratificación de riesgo y tratamiento de los pacientes con tromboembolia pulmonar

Uresandi, Fernando; Monreal, Manuel; García‐Bragado, F.; Domènech, Pere Pascual i; Lecumberri, Ramón; Escribano, Pilar; Zamorano, José Luís; Jiménez, Sònia; Ruiz-Artacho, Pedro; Lozano, Francisco; Romera, Antonio R.; Jiménez, David

doi:10.1016/j.arbres.2013.07.008

Cited by 70 publications

(14 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is a relatively common condition, ranging from 40–70% in the largest retrospective studies [ 3 , 5 ]. PE prevalence in our patients was particularly high, since the incidence of PE in acutely ill hospitalized medical patients on prophylaxis with enoxaparin is very low (0–0.4%) [ 20 – 22 ]. Our data do not allow us to distinguish whether PE started before or during admission.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of pulmonary embolism in patients with COVID-19 pneumonia and high D-dimer values: A prospective study

et al. 2020

View full text Add to dashboard Cite

bolic disease from the non-PE group. D-dimer, platelet count, and, C reactive protein values were significantly higher among PE patients. D-dimer values correlated with the radiologic magnitude of PE (p<0.001). Conclusions Patients with COVID-19 pneumonia and D-dimer values higher than 1 μg/mL presented a high prevalence of PE, regardless of clinical suspicion. We consider that these findings could contribute to improve the prognosis of patients with COVID-19 pneumonia, by initiating anticoagulant therapy when a PE is found.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of pulmonary embolism in patients with COVID-19 pneumonia and high D-dimer values: A prospective study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…According to recommendations in guidelines, we found that CTPA was increasingly used over time and that lung scintigraphy was frequently used in both diabetic and non‐diabetic men and women.…”

Section: Discussionmentioning

confidence: 99%

Type 2 diabetes is associated with a higher incidence of hospitalization for pulmonary embolism in Spain: Analysis of hospital discharge data during 2004–2013

et al. 2016

Self Cite

View full text Add to dashboard Cite

Background and objective: We compared the incidence and outcome of pulmonary embolism (PE) in individuals with and without type 2 diabetes mellitus (T2DM) in Spain during 2004-2013.Methods: The study was based on National Hospital Discharge Data, and the study population comprised patients hospitalized for PE. Annual incidence rates were classified according to T2DM status. In-hospital mortality (IHM), length of hospital stay (LOHS), comorbidities and use of diagnosis and therapeutic procedures were analysed. Results: We identified 123 872 discharges of patients (56 361 men and 67 511 women) with PE as their primary diagnosis (15.3% with T2DM). Incidence of discharge diagnoses of PE increased significantly in all groups. Crude rates were higher in diabetic patients. A positive association was identified between T2DM and PE: adjusted IRR was 2.00 (95% CI: 1.95-2.05) for men and 2.50 (95% CI: 2.45-2.57) for women. LOHS, readmissions and IHM decreased significantly for both groups. An association between IHM and risk factors (older age, Charlson comorbidity index >3, atrial fibrillation and cancer) was observed. T2DM was associated with higher IHM in men (OR: 1.22, 95% CI: 1.12-1.32) and women (OR: 1.24, 95% CI: 1.15-1.33). The use of computed tomography pulmonary angiography increased significantly overtime. Conclusion: We confirmed that in both men and women, diabetes was an independent risk factor for IHM. The incidence of discharge of patients with PE increased significantly during the study period. Diabetic

show abstract

“…Moreover, in some cases, these complications may also occur during anticoagulant treatment. Recurrent VTE, chronic thromboembolic pulmonary hypertension (CTPEH), and arterial thrombotic events are some of the possible complications, which are all related with a higher risk of death 10 , 11 …”

Section: Results Of Recordsmentioning

confidence: 99%

“…At the end of the active phase of treatment, therapeutic decisions are based on patient’s risk factors (presence of cancer, obesity, male, and idiopathic VTE), previous clinical history (thrombotic or haemorrhagic disease in the past, provoked, or unprovoked VTE), diagnostic assessment (thrombotic burden and persistence of RVD or PH), laboratory markers (D-dimer or thrombophilic mutations), 11 , 89 and the balance between the risk of bleeding and the advantage of preventing the recurrence of the VTE.…”

Section: Overview Of Medical and Surgical Therapymentioning

confidence: 99%

ANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism

D’Agostino

Zonzin

Enea

et al. 2017

European Heart Journal Supplements

View full text Add to dashboard Cite

Venous thromboembolism (VTE), including pulmonary embolism and deep venous thrombosis, is the third most common cause of cardiovascular death. The management of the acute phase of VTE has already been described in several guidelines. However, the management of the follow-up (FU) of these patients has been poorly defined. This consensus document, created by the Italian cardiologists, wants to clarify this issue using the currently available evidence in VTE. Clinical and instrumental data acquired during the acute phase of the disease are the cornerstone for planning the FU. Acquired or congenital thrombophilic disorders could be identified in apparently unprovoked VTE during the FU. In other cases, an occult cancer could be discovered after a VTE. The main targets of the post-acute management are to prevent recurrence of VTE and to identify the patients who can develop a chronic thromboembolic pulmonary hypertension. Knowledge of pathophysiology and therapeutic approaches is fundamental to decide the most appropriate long-term treatment. Moreover, prognostic stratification during the FU should be constantly updated on the basis of the new evidence acquired. Currently, the cornerstone of VTE treatment is represented by both the oral and the parenteral anticoagulation. Novel oral anticoagulants should be an interesting alternative in the long-term treatment.

show abstract

Consenso nacional sobre el diagnóstico, estratificación de riesgo y tratamiento de los pacientes con tromboembolia pulmonar

Cited by 70 publications

References 59 publications

Prevalence of pulmonary embolism in patients with COVID-19 pneumonia and high D-dimer values: A prospective study

Prevalence of pulmonary embolism in patients with COVID-19 pneumonia and high D-dimer values: A prospective study

Type 2 diabetes is associated with a higher incidence of hospitalization for pulmonary embolism in Spain: Analysis of hospital discharge data during 2004–2013

ANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism

Contact Info

Product

Resources

About